Hypertension: renal denervation is now also available for patients with chronic kidney disease

Renal denervation (RDN) is recognized as an innovative and safe therapy for the management of uncontrolled arterial hypertension and can now also be offered to patients with chronic kidney disease (CKD). Confirmation comes from the position paper published by the Italian Society of Nephrology (SIN).

Medtronic, a global leader in healthcare technology, endorses the Position Paper of the Italian Society of Nephrology (SIN), recently published in the Journal of Nephrology, which supports its use in patients with chronic kidney disease. This is the latest in a series of documents and statements endorsing renal denervation as an additional safe and effective therapeutic option to lower blood pressure in nephropathic patients with uncontrolled hypertension.

A consensus complementing international recommendations

The SIN Position Paper fits within the framework of the recent Guidelines of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC), which recognize renal denervation as the "third therapeutic pillar" alongside lifestyle modification and pharmacological therapy. These guidelines are based on robust clinical data, including results from Medtronic's global SPYRAL HTN program, which includes more than 5,000 patients and confirms the safety and long-term efficacy of the procedure in stably reducing blood pressure. Building on new and more recent clinical evidence, the SIN document expands current recommendations and supports the use of RDN in CKD patients.

The Position Paper represents an important step for clinical practice in Italy, expanding the indication of RDN to a complex and high-risk patient population, and confirms the validity of this procedure as an additional tool for blood pressure control in cases of hypertension not adequately managed by medication alone.

Documented benefits also in patients with chronic kidney disease

The SIN highlights that effective blood pressure control in CKD patients is essential to slow disease progression and reduce cardiovascular risk. Renal denervation enables a stable reduction in blood pressure without worsening kidney function, with additional benefits such as decreased albuminuria (abnormal presence of albumin in urine) and proteinuria (abnormal presence of proteins in urine), indicators of renal health protection.

The document also underlines positive results in three high-risk clinical settings: in patients with reduced renal function, in patients on dialysis, and in kidney transplant recipients, for whom the procedure has shown improved blood pressure control and long-term renal function stability.

Statements

"Reducing sympathetic nervous system activity in patients with chronic kidney disease is a key clinical goal. Renal denervation now offers a concrete tool to achieve this outcome, especially in cases where medications are insufficient or poorly tolerated," said dr. Sandro Feriozzi, expert in kidney disease.

"The extension of the indication to patients with chronic kidney disease confirms the scientific robustness of our technology and its value in daily clinical practice. This step demonstrates Medtronic's commitment to working with the nephrology and cardiology communities to improve patients' quality of life," said Vincenzo Angrisani, Medtronic Business Director CRDN, Italy, Greece and Israel.

A shared commitment to the treatment of hypertension

Medtronic's RDN technology is approved for commercial use in more than 75 countries and is supported by one of the most extensive research programs available, with over 30,000 patients treated worldwide. In the United States, the FDA approved renal denervation systems in 2023, while in Japan approval was obtained in September 2025.

The alignment between the Italian nephrology community and leading international scientific organizations further strengthens the position of renal denervation as a safe, effective, and evidence-based therapeutic option, supporting better blood pressure control and improved cardiovascular and renal protection.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission - to alleviate pain, restore health, and extend life - unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow us on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the U.S. Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:

Maria Enrica Orlandi
Public Relations
+39 346 1124979

Ryan Weispfenning
Investor Relations
+1-763-505-4626